Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 10:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 1,323 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Gastrointestinal Anomalies Clear all
Recruiting Not applicable Interventional

Personalized Mobile Health Platform to Promote Physical Activity in Adolescents and Young Adults With Cystic Fibrosis

NCT06616857
View directory record Official record
Conditions
Cystic Fibrosis (CF)
Interventions
NUDGE, Education
Behavioral · Other
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
13 Years to 25 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 15, 2026, 10:58 AM EDT
Recruiting No phase listed Observational

Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM)

NCT06837181
View directory record Official record
Conditions
Cystic Fibrosis (CF), Cystic Fibrosis-related Diabetes, Diabetes, Retinopathy, Neuropathy, Nephropathy, Blood Pressure, Cardiovascular Risk, Microvascular
Interventions
observational study
Other
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
12 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 15, 2026, 10:58 AM EDT
Recruiting Phase 2 Interventional

Utility of 18FDOPA PET/MRI for Focal Hyperinsulinism

NCT05088798
View directory record Official record
Conditions
Hyperinsulinism
Interventions
18F-Fluoro Dopa PET/MRI Imaging
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 15, 2026, 10:58 AM EDT
Completed Phase 3 Interventional Results available

Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT)

NCT01614457
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ivacaftor, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
6 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
29
States / cities
Birmingham, Alabama • Palo Alto, California • Hartford, Connecticut + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2015 · Synced Oct 15, 2026, 10:58 AM EDT
Completed Phase 2 Interventional Results available

Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation

NCT01225211
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Lumacaftor, Ivacaftor, Lumacaftor Placebo, Ivacaftor Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
38
States / cities
Birmingham, Alabama • Anchorage, Alaska • La Jolla, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2015 · Synced Oct 15, 2026, 10:58 AM EDT
Recruiting Phase 4 Interventional

Ensuring Access to Optimal Therapy in CF: The ENACT Study

NCT07148739
View directory record Official record
Conditions
Cystic Fibrosis (CF)
Interventions
Elexacaftor / Ivacaftor / Tezacaftor, therapeutic drug monitoring
Drug · Other
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
3 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
3
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 15, 2026, 10:58 AM EDT
Recruiting No phase listed Observational

Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)

NCT06193928
View directory record Official record
Conditions
Alagille Syndrome, Progressive Familial Intrahepatic Cholestasis
Interventions
Livmarli
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
8
States / cities
Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 15, 2026, 10:58 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

CF And Effects of Drugs Mixed Ex Vivo With Sputum for Mucolytic Treatment

NCT01533636
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 15, 2026, 10:58 AM EDT
Recruiting Phase 2 Interventional

Metformin for People With CFRD on CFTR Modulator Therapy to Improve Ion Channel Function

NCT04530383
View directory record Official record
Conditions
Cystic Fibrosis-related Diabetes, Cystic Fibrosis
Interventions
Metformin Hydrochloride
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 15, 2026, 10:58 AM EDT
Completed Phase 1 Interventional

A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP)

NCT02452372
View directory record Official record
Conditions
Acute Intermittent Porphyria
Interventions
givosiran (ALN-AS1), Sterile Normal Saline (0.9% NaCl)
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
4
States / cities
Birmingham, Alabama • San Francisco, California • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Oct 15, 2026, 10:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of Lactobacillus Reuteri (L. Reuteri) in Healthy Adults

NCT00922727
View directory record Official record
Conditions
Colic, Gastrointestinal Tract Infections
Interventions
L. reuteri, Sunflower Oil
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 25, 2018 · Synced Oct 15, 2026, 10:58 AM EDT
Completed Phase 3 Interventional Results available

GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study

NCT02525861
View directory record Official record
Conditions
Alpha1-antitrypsin Deficiency
Interventions
GLASSIA
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
17
States / cities
Tucson, Arizona • Los Angeles, California • Sacramento, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 15, 2026, 10:58 AM EDT
Completed No phase listed Observational

Registry for Women Who Are At Risk Or May Have Lynch Syndrome

NCT00508573
View directory record Official record
Conditions
Hereditary Nonpolyposis Colorectal Cancer, Lynch Syndrome
Interventions
Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 15, 2026, 10:58 AM EDT
Completed No phase listed Observational

Immune System and Gut Abnormalities in Patients With Common Variable Immunodeficiency With and Without Gastrointestinal Symptoms

NCT00015431
View directory record Official record
Conditions
Common Variable Immunodeficiency
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
10 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 29, 2019 · Synced Oct 15, 2026, 10:58 AM EDT
Available No phase listed Expanded access

Expanded Access Program of Bitopertin For Participants With EPP or XLP

NCT07603401
View directory record Official record
Conditions
Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP)
Interventions
DISC-1459
Drug
Lead sponsor
Disc Medicine, Inc
Industry
Eligibility
12 Years and older
U.S. locations
7
States / cities
Miami, Florida • Boston, Massachusetts • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 15, 2026, 10:58 AM EDT
Completed Not applicable Interventional Results available

Open-label Vitamin D Trial for Patients With Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis

NCT01222273
View directory record Official record
Conditions
Cystic Fibrosis, Allergic Bronchopulmonary Aspergillosis
Interventions
cholecalciferol (Vitamin D3)
Dietary Supplement
Lead sponsor
University of Pittsburgh
Other
Eligibility
12 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 15, 2026, 10:58 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of Hepatic Glucose Production and De Novo Lipogenesis in Patients With Cystic Fibrosis

NCT00014781
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 30 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2001
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2009 · Synced Oct 15, 2026, 10:58 AM EDT
Completed Phase 2 Interventional

8 Weeks Treatment With DDP225 in Patients With Diarrhea Predominant IBS

NCT00230581
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
DDP225
Drug
Lead sponsor
Dynogen Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
5
States / cities
Scottsdale, Arizona • St Louis, Missouri • Great Neck, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2007 · Synced Oct 15, 2026, 10:58 AM EDT
Completed Phase 3 Interventional

Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism

NCT03941236
View directory record Official record
Conditions
Congenital Hyperinsulinism
Interventions
dasiglucagon
Drug
Lead sponsor
Zealand Pharma
Industry
Eligibility
5 Weeks to 13 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
3
States / cities
Aurora, Colorado • Philadelphia, Pennsylvania • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 15, 2026, 10:58 AM EDT
Completed Phase 2 Interventional

Randomized, Controlled Trial of S-adenosylmethionine in Alcoholic Liver Disease

NCT00851981
View directory record Official record
Conditions
Alcoholic Hepatitis
Interventions
Placebo, SAMe
Other · Dietary Supplement
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Sep 13, 2010 · Synced Oct 15, 2026, 10:58 AM EDT
Completed Phase 3 Interventional Results available

Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del

NCT03601637
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
LUM, IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Months to 23 Months
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
24
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Palo Alto, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2023 · Synced Oct 15, 2026, 10:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants

NCT04526210
View directory record Official record
Conditions
Wilson Disease
Interventions
ALXN1840, Bupropion Hydrochloride
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced Oct 15, 2026, 10:58 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Impact of B. Adolescentis iVS-1 Probiotic on Gastrointestinal Outcomes

NCT07408518
View directory record Official record
Conditions
Digestive Disease, Gut Health
Interventions
Probiotic, Placebo
Dietary Supplement · Other
Lead sponsor
Synbiotic Health
Industry
Eligibility
18 Years to 75 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 15, 2026, 10:58 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Hirschsprung Disease Genetic Study

NCT00478712
View directory record Official record
Conditions
Hirschsprung Disease
Interventions
Identification of genetic causes of Hirschsprung Disease
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
1 Week to 100 Years
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 15, 2026, 10:58 AM EDT